New way of treatment – First-line treatment of PD has since long been per oral administration of the dopamine precursor levodopa in combination with an enzyme inhibitor, carbidopa, preventing the conversion of levodopa to dopamine outside the brain. In late stages of the disorder, the fluctuating serum levels of levodopa following this regimen however often results in rapid switches between reduced mobility and involuntary movements, so called on-off. Infudopa©, is the umbrella term for infusion solutions developed by Dizlin that contain levodopa and carbidopa. Infudopa© may be administered through intravenous injection, short-term intravenous infusion (Infudopa® IntraV) and long-term continuous subcutaneous infusion (Infudopa© SubC), respectively. By providing rapid and stable serum levels of levodopa, these treatments will improve the condition of subjects suffering from on-off as well as of those requiring rapid symptom relief from marked hypokinesia. In the near future, patients with PD may hence be treated in the same way as insulin-dependent diabetes patients. i.e. through continuous subcutaneous infusion using a small pump.